Institut Català de la Salut
[Serrano Gómez G, Soler Z, Pons Tarin M, Mayorga L, Manjón I, Vega Abellaneda S] Microbiome Lab, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Yañez F, Herrera deGuise C, Borruel N] Microbiome Lab, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rodriguez Sinovas A, Consegal M] Grup de Recerca de Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Manichanh C] Microbiome Lab, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. CIBER of Hepatic and Digestive Diseases (CIBERehd), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-08-25T06:47:12Z
2025-08-25T06:47:12Z
2025-06-16
Inflammatory bowel disease; Microbiome; Multi-omics
Enfermedad inflamatoria intestinal; Microbioma; Multiómica
Malaltia inflamatòria intestinal; Microbioma; Multiòmica
Background The gut microbiome plays a key role in the development of inflammatory bowel disease (IBD), as imbalances in microbial composition are associated with immune dysfunction. However, the specific mechanisms by which certain microorganisms contribute to this process remain unclear. Methods Here, we employed a multi-omics approach on fecal samples to identify novel microbiome markers and elucidate mechanisms underlying IBD. Shotgun metagenomics was applied to 212 samples (850 in total with validation cohort), shotgun metatranscriptomics to 103 samples and metabolomics to 105 samples. Machine learning techniques were used to predict disease and the three omics data were integrated to propose a mechanistic role of the microbiota. Results Metagenomic analysis identified Crohn's disease (CD)-specific microbiome signatures, including a panel of 20 species that achieved a high diagnostic performance, with an area under the ROC curve (AUC) of 0.94 in an external validation set. Metatranscriptomic analysis revealed significant alterations in microbial fermentation pathways in CD, but not in ulcerative colitis (UC), highlighting disruptions that explain the depletion of butyrate—a key anti-inflammatory metabolite—observed in metabolomics analysis. Integrative multi-omics analyses further identified active virulence factor genes in CD, predominantly originating from the adherent-invasive Escherichia coli (AIEC). Notably, these findings unveiled novel mechanisms, including E. coli-mediated aspartate depletion and the utilization of propionate, which drives the expression of the ompA virulence gene, critical for bacterial adherence and invasion of the host’s macrophages. Interestingly, these microbiome alterations were absent in UC, underscoring distinct mechanisms of disease development between the two IBD subtypes. Conclusions In conclusion, our study not only identifies promising novel biomarkers with strong diagnostic potential, which could be valuable in challenging clinical scenarios, but also offers an integrated multi-omics perspective on the microbial mechanisms underlying inflammation and virulence in Crohn's disease.
This work was supported by the Instituto de Salud Carlos III/FEDER (PI20/00130; FI21/00262). Marc Pons and Sara Vega-Abellaneda were supported by the AGAUR (2021 SGR 00459). Francisca Yáñez was supported by a fellowship from ANID, BECAS Chile, No. 72190278.
Artículo
Versión publicada
Inglés
Marcadors bioquímics; Crohn, Malaltia de; Intestins - Microbiologia; Intestins - Inflamació; Escheríchia coli; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases; PHENOMENA AND PROCESSES::Microbiological Phenomena::Microbiota::Gastrointestinal Microbiome; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease; ORGANISMS::Bacteria::Gram-Negative Bacteria::Gram-Negative Facultatively Anaerobic Rods::Enterobacteriaceae::Escherichia::Escherichia coli; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal; FENÓMENOS Y PROCESOS::fenómenos microbiológicos::microbiota::microbiota intestinal; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn; ORGANISMOS::Bacteria::bacterias gramnegativas::bacilos gramnegativos anaerobios facultativos::Enterobacteriaceae::Escherichia::Escherichia coli
BMC
Biomarker Research;13
https://doi.org/10.1186/s40364-025-00802-1
info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00130
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/FI21%2F00262
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]